NantCell Announces New Celgene Investment

Immunotherapy Company Will Present Findings at the JP Morgan Healthcare Conference in San Francisco on January 7thSecond Round Crossover Funding Brings Celgene’s Investment to $105M in NantCellValued at $4 BillionCurrently Enrolling Patients in Advanced Stage Trials...